Testing a drug for low platelets during cancer treatment
Treatments studied
Part of Cancer clinical trials.
This study looks at whether a drug called Heptapopal Ethanolamine can help raise low platelet counts caused by chemo or radiation therapy for cancer. It is for people age 18 and older who are getting cancer treatment and have low platelets or a big drop in platelets.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You are currently getting chemotherapy or radiation therapy for cancer
- Your platelet count is 100 or lower, or has dropped at least 50 points, or your doctor says you need preventive treatment
- You are not allergic to the study drug or its ingredients
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational pill (hetrombopag) to see if it can safely raise platelet counts in people with solid tumors whose platelets drop after chemotherapy. If you are receiving platinum- or gemcitabine-based chemo and have low platelets due to chemo, this trial may be an option.
This trial tests a drug called hetrombopag to help raise platelet counts in women whose cancer therapy has caused low platelets. The goal is to see if it can safely prevent the need for platelet transfusions.
This study tests if a combination of two medications, hetrombopag (a pill) and rhTPO (an injection), can safely raise very low platelet counts in people with solid tumors caused by their cancer treatments. If you have low platelets due to chemo, radiation, or other therapies, this may offer a new option.
This trial tests a pill called herombopag to prevent low platelets caused by chemo and radiation for cervical cancer. The goal is to see if it can help keep your platelet levels safe so you can complete your treatment.
This Phase 2 trial studies herombopag to raise very low platelet counts caused by chemotherapy and reduce bleeding risk. It may help people whose platelet levels stay too low even after prior standard attempts like rhTPO or IL-11.
This Phase 2 study tests hetrombopag to treat chemotherapy-related low platelet counts in adults with acute myeloid leukemia (AML) in remission. It aims to help keep platelets up so you can safely continue chemotherapy.
Hear when a new Cancer, Therapy-Related trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.